Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nuvectis Pharma, Inc. - Common Stock (NQ: NVCT )

6.740 +0.020 (+0.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,561
Open 6.810
Bid (Size) 6.660 (1)
Ask (Size) 6.750 (4)
Prev. Close 6.720
Today's Range 6.560 - 6.817
52wk Range 5.850 - 15.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market
Via AB Newswire
Precision Medicine M&A is Transforming the Future of the Biotech Industry
Via AB Newswire

Performance

YTD
-18.70%
-18.70%
1 Month
-4.40%
-4.40%
3 Month
-5.07%
-5.07%
6 Month
-5.47%
-5.47%
1 Year
-53.68%
-53.68%

More News

Read More
7 Penny Biotech Stocks to Triple Your Investment
Via InvestorPlace
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Recap: Nuvectis Pharma Q3 Earnings
Via Benzinga
NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024
Via InvestorPlace
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
From Nuvectis Pharma, Inc.
Via GlobeNewswire
5 Healthcare Stocks to Buy for 2024
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma to Present at the 36th Annual Roth Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
From Nuvectis Pharma, Inc.
Via GlobeNewswire
NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023
Via InvestorPlace
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
From Nuvectis Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
From Nuvectis Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.